Thierry ANDRE
Hôpital Sainte Antoine - Paris - France · Saint-Antoine Hospital · Hôpital Saint Antoine PARIS
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thierry ANDRE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06333314 · Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIUNICANCER · recruiting · Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma · principal investigator
- Ph2NCT06059495 · DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyGERCOR - Multidisciplinary Oncology Cooperative Group · recruiting · Adenocarcinoma - GEJ, Gastric Adenocarcinoma · principal investigator
- Ph2NCT04006262 · Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.GERCOR - Multidisciplinary Oncology Cooperative Group · active not recruiting · Localized Oesogastric Adenocarcimona, MSI and or dMMR · principal investigator
- Ph3NCT03869892 · Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.Institut de Recherches Internationales Servier · active not recruiting · Metastatic Colorectal Cancer · principal investigator
- N/ANCT03422601 · Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin TreatmentGERCOR - Multidisciplinary Oncology Cooperative Group · unknown · Colorectal Cancer, Stage III Colon Cancer · study director
- Ph2NCT03350126 · iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabGERCOR - Multidisciplinary Oncology Cooperative Group · active not recruiting · Metastatic Cancer Colorectal · principal investigator
- Ph3NCT02967289 · IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant SettingUNICANCER · completed · Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) · study chair
- Ph2NCT02699073 · Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With RegorafenibGERCOR - Multidisciplinary Oncology Cooperative Group · completed · Metastatic Colorectal Cancer · principal investigator
- Ph3NCT00958737 · Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon CancerGERCOR - Multidisciplinary Oncology Cooperative Group · unknown · Colorectal Cancer · principal investigator
- Ph2NCT00655499 · Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal CancerGERCOR - Multidisciplinary Oncology Cooperative Group · completed · Colorectal Cancer · principal investigator
- Ph3NCT00189657 · 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal CancerAssociation Européenne de Recherche en Oncologie · unknown · Cancer of the Rectum · principal investigator
- Ph2NCT00072553 · Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal CancerGERCOR - Multidisciplinary Oncology Cooperative Group · unknown · Colorectal Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:21 UTC. The ranking covers the 200 most relevant of 149 PubMed records, and a shared surname and initials can bring in a namesake. All 149 on PubMed
- Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.N Engl J Med · 20042,977 citationsRCR 67.8
- Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med · 20202,523 citationsRCR 109.5
- FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol · 20042,391 citationsRCR 56.2
- 2,327 citationsRCR 75.2
- Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.J Clin Oncol · 20091,775 citationsRCR 45.0
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.Lancet Oncol · 2013966 citationsRCR 26.6
- 884 citationsRCR 31.2
- 834 citationsRCR 57.3
- 813 citationsRCR 18.8
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.J Clin Oncol · 2020810 citationsRCR 32.3